Ligand Pharmaceuticals IncorporatedLGNDNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+182.4%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+182.4%/yr
vs +35.9%/yr prior
Acceleration
+146.5pp
Accelerating
Percentile
P100
Near historical high
vs 3Y Ago
22.5x
Strong expansion
Streak
2 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2025 | 278.91% |
| 2024 | -12.68% |
| 2023 | -32.00% |
| 2022 | 12.39% |
| 2021 | -20.73% |
| 2020 | -27.55% |
| 2019 | 100.65% |
| 2018 | 3.63% |
| 2017 | 26.70% |
| 2016 | 58.60% |